Hemostemix has received a $250,000 Letter of Commitment
Hemostemix, an autologous stem cell therapy company, has received a $250,000 letter of commitment for funding from the McGill University Health Care Foundation.
Under the Letter of Commitment, the MUHC Foundation will fund $250,000 of the clinical trial expenses and partner with Hemostemix, Dr. Nadia Giannetti and Dr. Renzo Cecere to complete a phase II double blind randomized clinical trial of ACP-01 as a treatment of ischemic cardiomyopathy at the McGill University Health Centre.
Hemostemix Obtains all Clinical Trial Data and Announces $2.5 Million Unit Offering
The company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases not adequately addressed by current therapeutics. The company is looking to raise gross proceeds of up to $2.5 million from the placement of up to 250 million units priced at $0.01 per unit.
Hemostemix Announced a Non-Brokered Private Placement
The company is looking to raise gross proceeds of up to $650,000 from the placement of up to 65 million units priced at $0.01 per unit. The units consist of 1 share and 1 warrant, with each warrant exercisable at $0.05 for 12 months, subject to an acceleration clause.
Benefits of Hemostemix Autologous Stem Cell Therapy
In a recent InvestorIntel interview, Peter Clausi speaks with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc., about using Hemostemix’s patented autologous stem cell therapy platform to treat Ischemia and Angina with significant success in more than 500 patients.
homas went on to give an introduction about the origin of the company and talked about the strong management team and well known board members. “I have come across some good technologies and put together a team that have succeeded,” Thomas commented.
Thomas also provided an update on Hemostemix’s ACP-01 Phase 2 Clinical Trials. ACP-01 uses a patient’s own cells to restore blood flow to ischemic limbs and has the potential to treat a range of ischemic diseases.
Hemostemix’s Autologous Stem Cell Therapy and Why He Calls The Technology “The Fountain of Youth.”
In this InvestorIntel interview, Thomas went on to say that Hemostemix’s lead product ACP-01 works by treating ischemia (lack of blood circulation) in a patient’s body. The technology has already been used to treat around 500 patients suffering from ischemia in the heart, arteries, and limb.
He added that using the technology many patients were able to “save their limbs from otherwise certain amputations.” Hemostemix has 91 patents including a patent on the automation of production which enables the company to scale the business “exponentially” as over a million patients lose their limbs to amputation in North America alone.
The technology is now in Phase 2 clinical trial.
Co-founder, Thomas Smeenk about Hemostemix’s technology that uses patients own blood to treat ischemia in the circulatory system of the body.
Co-founder, Thomas Smeenk talks about Hemostemix achieving a major milestone this week by announcing it had successfully settled all litigation regarding its ownership of its intellectual property and the market’s immediate positive reaction.
Co-founder, Thomas Smeenk talks about the Phase II Clinical Trial on Hemostemix’s ACP-01 which has the potential to treat patients with severe critical limb ischemia.
Co-founder, Thomas Smeenk talks about the Phase II Clinical Trial on Hemostemixs ACP-01 which has the potential to treat patients with severe critical limb ischemia.